{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T23:16:52Z","timestamp":1787008612441,"version":"build-2736575974"},"reference-count":28,"publisher":"Oxford University Press (OUP)","issue":"11","license":[{"start":{"date-parts":[[2020,10,12]],"date-time":"2020-10-12T00:00:00Z","timestamp":1602460800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100005564","name":"Gilead Sciences","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005564","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021,6,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Treatment with vesatolimod, an investigational, oral, toll-like receptor 7 (TLR7) agonist, leads to sustained viral remission in some non-human primates when combined with anti-envelope antibodies or therapeutic vaccines. We report results of a Phase Ib study evaluating safety, pharmacokinetics, and pharmacodynamics of vesatolimod in adults living with human immunodeficiency virus (HIV)\u20131.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>In this double-blind, multicenter, placebo-controlled trial, participants on antiretroviral therapy with screening plasma HIV-1 RNA levels &amp;lt;50 copies\/mL were randomized (6:2) to receive 6\u201310 doses of vesatolimod (1\u201312 mg) or matching placebo orally every other week in sequential dose-escalation cohorts. The primary study objectives included establishing the safety and virologic effects of vesatolimod (change from baseline in plasma HIV-1 RNA). Pharmacokinetics and pharmacodynamic\/immunologic activity were assessed as secondary objectives.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>A total of 48 individuals were randomly assigned to vesatolimod (n\u2005=\u200536) or placebo (n\u2005=\u200512). Vesatolimod was generally well tolerated, with no study drug\u2013related serious adverse events or adverse events leading to study drug discontinuation. There were no statistically significant changes from baseline in plasma HIV-1 RNA in the vesatolimod groups, compared to placebo.<\/jats:p>\n                    <jats:p>Vesatolimod plasma exposures increased dose proportionally; consistent responses in cytokines, interferon-stimulated gene expression, and lymphocyte activation were observed with increasing dose levels above 4 mg. Peak elevations 24 hours after receipt of a 6 mg dose were &amp;gt;3.9-fold higher for interferon gamma-induced protein 10 (IP-10), interleukin-1 receptor antagonist (IL-1RA), interferon\u2013inducible T-cell alpha chemoattractant (ITAC) when compared to baseline values.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Vesatolimod was well tolerated at doses ranging from 1 to 12 mg. Immune stimulation was observed at doses above 4 mg, providing rationale for future combination trials in people living with HIV.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Clinical Trials Registration<\/jats:title>\n                    <jats:p>NCT02858401.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/cid\/ciaa1534","type":"journal-article","created":{"date-parts":[[2020,10,6]],"date-time":"2020-10-06T15:15:43Z","timestamp":1601997343000},"page":"e815-e824","source":"Crossref","is-referenced-by-count":72,"title":["Vesatolimod, a Toll-like Receptor 7 Agonist, Induces Immune Activation in Virally Suppressed Adults Living With Human Immunodeficiency Virus\u20131"],"prefix":"10.1093","volume":"72","author":[{"given":"Sharon A","family":"Riddler","sequence":"first","affiliation":[{"name":"Department of Medicine, University of Pittsburgh, Pittsburgh, Pennsylvania, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Para","sequence":"additional","affiliation":[{"name":"Wexner Medical Center, The Ohio State University, Columbus, Ohio, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Constance A","family":"Benson","sequence":"additional","affiliation":[{"name":"Department of Medicine, University of California San Diego, San Diego, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anthony","family":"Mills","sequence":"additional","affiliation":[{"name":"SoCal Men\u2019s Medical Group, Los Angeles, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Moti","family":"Ramgopal","sequence":"additional","affiliation":[{"name":"Midway Specialty Care Center, Fort Pierce, Florida, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edwin","family":"DeJesus","sequence":"additional","affiliation":[{"name":"Orlando Immunology Center, Orlando, Florida, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cynthia","family":"Brinson","sequence":"additional","affiliation":[{"name":"Central Texas Clinical Research, Austin, Texas, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joshua","family":"Cyktor","sequence":"additional","affiliation":[{"name":"Department of Medicine, University of Pittsburgh, Pittsburgh, Pennsylvania, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jana","family":"Jacobs","sequence":"additional","affiliation":[{"name":"Department of Medicine, University of Pittsburgh, Pittsburgh, Pennsylvania, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dianna","family":"Koontz","sequence":"additional","affiliation":[{"name":"Department of Medicine, University of Pittsburgh, Pittsburgh, Pennsylvania, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John W","family":"Mellors","sequence":"additional","affiliation":[{"name":"Department of Medicine, University of Pittsburgh, Pittsburgh, Pennsylvania, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gregory M","family":"Laird","sequence":"additional","affiliation":[{"name":"Accelevir Diagnostics, Baltimore, Maryland, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Terri","family":"Wrin","sequence":"additional","affiliation":[{"name":"Monogram Biosciences, South San Francisco, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heena","family":"Patel","sequence":"additional","affiliation":[{"name":"Gilead Sciences Inc., Foster City, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan","family":"Guo","sequence":"additional","affiliation":[{"name":"Gilead Sciences Inc., Foster City, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey","family":"Wallin","sequence":"additional","affiliation":[{"name":"Gilead Sciences Inc., Foster City, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jillian","family":"Boice","sequence":"additional","affiliation":[{"name":"Department of Medicine, University of Pittsburgh, Pittsburgh, Pennsylvania, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liao","family":"Zhang","sequence":"additional","affiliation":[{"name":"Gilead Sciences Inc., Foster City, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rita","family":"Humeniuk","sequence":"additional","affiliation":[{"name":"Gilead Sciences Inc., Foster City, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rebecca","family":"Begley","sequence":"additional","affiliation":[{"name":"Gilead Sciences Inc., Foster City, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Polina","family":"German","sequence":"additional","affiliation":[{"name":"Gilead Sciences Inc., Foster City, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiba","family":"Graham","sequence":"additional","affiliation":[{"name":"Gilead Sciences Inc., Foster City, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Romas","family":"Geleziunas","sequence":"additional","affiliation":[{"name":"Gilead Sciences Inc., Foster City, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diana M","family":"Brainard","sequence":"additional","affiliation":[{"name":"Gilead Sciences Inc., Foster City, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Devi","family":"SenGupta","sequence":"additional","affiliation":[{"name":"Gilead Sciences Inc., Foster City, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2020,10,12]]},"reference":[{"key":"2021060106111981000_CIT0001","doi-asserted-by":"crossref","first-page":"2450","DOI":"10.3389\/fimmu.2019.02450","article-title":"Targeting cellular and tissue HIV reservoirs with toll-like receptor agonists","volume":"10","author":"Macedo","year":"2019","journal-title":"Front Immunol"},{"key":"2021060106111981000_CIT0002","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1016\/j.immuni.2018.04.030","article-title":"Targeting the latent reservoir for HIV-1","volume":"48","author":"Sengupta","year":"2018","journal-title":"Immunity"},{"key":"2021060106111981000_CIT0003","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1038\/nrmicro3352","article-title":"Eradicating HIV-1 infection: seeking to clear a persistent pathogen","volume":"12","author":"Archin","year":"2014","journal-title":"Nat Rev Microbiol"},{"key":"2021060106111981000_CIT0004","doi-asserted-by":"crossref","first-page":"aaf6517","DOI":"10.1126\/science.aaf6517","article-title":"Latency reversal and viral clearance to cure HIV-1","volume":"353","author":"Margolis","year":"2016","journal-title":"Science"},{"key":"2021060106111981000_CIT0005","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1172\/JCI86047","article-title":"Recent developments in the effort to cure HIV infection: going beyond n\u2005=\u20051","volume":"126","author":"Siliciano","year":"2016","journal-title":"J Clin Invest"},{"key":"2021060106111981000_CIT0006","doi-asserted-by":"crossref","first-page":"e64219","DOI":"10.1371\/journal.pone.0064219","article-title":"A single HIV-1 cluster and a skewed immune homeostasis drive the early spread of HIV among resting CD4+ cell subsets within one month post-infection","volume":"8","author":"Bacchus","year":"2013","journal-title":"PLOS One"},{"key":"2021060106111981000_CIT0007","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/S0140-6736(10)60676-9","article-title":"Antiretroviral therapy and management of HIV infection","volume":"376","author":"Volberding","year":"2010","journal-title":"Lancet"},{"key":"2021060106111981000_CIT0008","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1089\/aid.2017.0310","article-title":"Shifting the HIV paradigm from care to cure: proceedings from the Caribbean Expert Summit in Barbados, August 2017","volume":"34","author":"Landis","year":"2018","journal-title":"AIDS Res Hum Retroviruses"},{"key":"2021060106111981000_CIT0009","doi-asserted-by":"crossref","first-page":"e02166-16","DOI":"10.1128\/JVI.02166-16","article-title":"Toll-like receptor 7 agonist GS-9620 induces HIV expression and HIV-specific immunity in cells from HIV-infected individuals on suppressive antiretroviral therapy","volume":"91","author":"Tsai","year":"2017","journal-title":"J Virol"},{"key":"2021060106111981000_CIT0010","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aao4521","article-title":"TLR7 agonists induce transient viremia and reduce the viral reservoir in SIV-infected rhesus macaques on antiretroviral therapy","volume":"10","author":"Lim","year":"2018","journal-title":"Sci Transl Med"},{"key":"2021060106111981000_CIT0011","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1038\/nature20583","article-title":"Ad26\/MVA therapeutic vaccination with TLR7 stimulation in SIV-infected rhesus monkeys","volume":"540","author":"Borducchi","year":"2016","journal-title":"Nature"},{"key":"2021060106111981000_CIT0012","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1038\/s41586-018-0600-6","article-title":"Antibody and TLR7 agonist delay viral rebound in SHIV-infected monkeys","volume":"563","author":"Borducchi","year":"2018","journal-title":"Nature"},{"key":"2021060106111981000_CIT0013","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.127717","article-title":"TLR7 agonist administration to SIV-infected macaques receiving early initiated cART does not induce plasma viremia","volume":"4","author":"Del Prete","year":"2019","journal-title":"JCI Insight"},{"key":"2021060106111981000_CIT0014","doi-asserted-by":"crossref","first-page":"e01163-19","DOI":"10.1128\/AAC.01163-19","article-title":"PD-1 blockade and TLR7 activation lack therapeutic benefit in chronic simian immunodeficiency virus\u2013infected macaques on antiretroviral therapy","volume":"63","author":"Bekerman","year":"2019","journal-title":"Antimicrob Agents Chemother"},{"key":"2021060106111981000_CIT0015","doi-asserted-by":"crossref","first-page":"1508","DOI":"10.1053\/j.gastro.2013.02.003","article-title":"GS-9620, an oral agonist of toll-like receptor-7, induces prolonged suppression of hepatitis B virus in chronically infected chimpanzees","volume":"144","author":"Lanford","year":"2013","journal-title":"Gastroenterology"},{"key":"2021060106111981000_CIT0016","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1111\/jvh.12942","article-title":"Safety and efficacy of vesatolimod (GS-9620) in patients with chronic hepatitis B who are not currently on antiviral treatment","volume":"25","author":"Agarwal","year":"2018","journal-title":"J Viral Hepat"},{"key":"2021060106111981000_CIT0017","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1016\/j.jhep.2017.10.027","article-title":"Safety, efficacy and pharmacodynamics of vesatolimod (GS-9620) in virally suppressed patients with chronic hepatitis B","volume":"68","author":"Janssen","year":"2018","journal-title":"J Hepatol"},{"key":"2021060106111981000_CIT0018","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1016\/j.jhep.2015.02.037","article-title":"The oral toll-like receptor-7 agonist GS-9620 in patients with chronic hepatitis B virus infection","volume":"63","author":"Gane","year":"2015","journal-title":"J Hepatol"},{"key":"2021060106111981000_CIT0019","doi-asserted-by":"crossref","first-page":"409","DOI":"10.3851\/IMP2548","article-title":"Safety, pharmacokinetics and pharmacodynamics of GS-9620, an oral toll-like receptor 7 agonist","volume":"18","author":"Lopatin","year":"2013","journal-title":"Antivir Ther"},{"key":"2021060106111981000_CIT0020","doi-asserted-by":"crossref","first-page":"3944","DOI":"10.1128\/JCM.02060-14","article-title":"Improved single-copy assays for quantification of persistent HIV-1 viremia in patients on suppressive antiretroviral therapy","volume":"52","author":"Cillo","year":"2014","journal-title":"J Clin Microbiol"},{"key":"2021060106111981000_CIT0021","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1097\/01.qai.0000557991.80452.a5","article-title":"Nonhuman primate models in the study of early events in AIDS virus infection","volume":"81","author":"Lifson","year":"2019","journal-title":"J Acquir Immune Defic Syndr"},{"key":"2021060106111981000_CIT0022","doi-asserted-by":"crossref","first-page":"1686","DOI":"10.1093\/cid\/cix201","article-title":"Short-course toll-like receptor 9 agonist treatment impacts innate immunity and plasma viremia in individuals with human immunodeficiency virus infection","volume":"64","author":"Vibholm","year":"2017","journal-title":"Clin Infect Dis"},{"key":"2021060106111981000_CIT0023","doi-asserted-by":"crossref","first-page":"e1005142","DOI":"10.1371\/journal.ppat.1005142","article-title":"The depsipeptide romidepsin reverses HIV-1 latency in vivo","volume":"11","author":"S\u00f8gaard","year":"2015","journal-title":"PLOS Pathog"},{"key":"2021060106111981000_CIT0024","article-title":"Multidose IV romidepsin: no increased HIV-1 expression in persons on ART, ACTG A5315","author":"McMahon","journal-title":"Presented at the Conference of Retroviruses and Opportunistic Infections 2019, 4-7 March, Seattle, WA. Available at: https:\/\/www.croiconference.org\/abstract\/multidose-iv-romidepsin-no-increased-hiv-1-expression-persons-art-actg-a5315\/. Accessed 26 Oct 2020"},{"key":"2021060106111981000_CIT0025","first-page":"522","article-title":"Inflammatory and immunometabolic consequences of gut dysfunction in HIV: parallels with IBD and implications for reservoir persistence and non-AIDS comorbidities","volume":"46","author":"Alzahrani","year":"2019","journal-title":"E Bio Medicine"},{"key":"2021060106111981000_CIT0026","doi-asserted-by":"crossref","DOI":"10.3851\/IMP3359","article-title":"Activation of HIV-specific CD8+ T-cells from HIV+ donors by vesatolimod","author":"Ram","year":"2020","journal-title":"Antivir Ther [Preprint]"},{"key":"2021060106111981000_CIT0027","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1111\/imr.12823","article-title":"T-cell exhaustion in HIV infection","volume":"292","author":"Fenwick","year":"2019","journal-title":"Immunol Rev"},{"key":"2021060106111981000_CIT0028","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1007\/s00281-018-0712-y","article-title":"Female predisposition to TLR7-driven autoimmunity: gene dosage and the escape from X chromosome inactivation","volume":"41","author":"Souyris","year":"2019","journal-title":"Semin Immunopathol"}],"container-title":["Clinical Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/cid\/advance-article-pdf\/doi\/10.1093\/cid\/ciaa1534\/34788251\/ciaa1534.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/cid\/article-pdf\/72\/11\/e815\/38389378\/ciaa1534.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/cid\/article-pdf\/72\/11\/e815\/38389378\/ciaa1534.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T03:52:23Z","timestamp":1622519543000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/cid\/article\/72\/11\/e815\/5921029"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,10,12]]},"references-count":28,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2020,10,12]]},"published-print":{"date-parts":[[2021,6,1]]}},"URL":"https:\/\/doi.org\/10.1093\/cid\/ciaa1534","relation":{},"ISSN":["1058-4838","1537-6591"],"issn-type":[{"value":"1058-4838","type":"print"},{"value":"1537-6591","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2021,6,1]]},"published":{"date-parts":[[2020,10,12]]}}}